Study on the Anticancer Drug 5-Fluorouracil-Conjugated Polyaspartamide Containing Hepatocyte-Targeting Group

Anticancer conjugates of 5-fluorouracil (5-Fu) and polyaspartamide, containing pyridoxamine as the hepatocyte-targeting group, were synthesized and characterized. Their sustained release properties and biodistribution were evaluated. The 5-Fu was targeted to specific organs, such as the liver, and h...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bioactive and compatible polymers 2001-07, Vol.16 (4), p.277-293
Main Authors: Yan, Guo-Ping, Zhuo, Ren-Xi, Zheng, Cong-Yi
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Gastroenterology. Liver. Pancreas. Abdomen
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Pharmacology. Drug treatments
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticancer conjugates of 5-fluorouracil (5-Fu) and polyaspartamide, containing pyridoxamine as the hepatocyte-targeting group, were synthesized and characterized. Their sustained release properties and biodistribution were evaluated. The 5-Fu was targeted to specific organs, such as the liver, and had a sustained in vitro release rate in PBS. In vitro cytotoxicity assay showed that the polymeric drugs exhibited low cytotoxicity to the human liver cells (L-02). These polymeric drugs possess high anticancer efficiencies and induced apoptosis in the human hepatic tumor cells (Bel-7204).
ISSN:0883-9115
1530-8030
DOI:10.1106/M4LK-LWJQ-34CL-LR85